Literature DB >> 18025114

Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.

David Zhuang1, Melinda Smedema, Ann Lemonte, Benita K Book, Mark D Pescovitz, L Joseph Wheat.   

Abstract

Calcineurin inhibitors may augment the effects of antifungal drugs in microbiological assays. We examined this interaction in a microbiological assay for posaconazole. No effect was observed. However, concurrent or recently discontinued treatment with other antifungal drugs caused false-positive results, emphasizing a limitation of microbiological assays for antifungal drug level measurement.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18025114      PMCID： PMC2224727          DOI： 10.1128/AAC.01096-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS.

Authors:  W Feng; H Liu; G Chen; R Malchow; F Bennett; E Lin; B Pramanik; T M Chan
Journal:  J Pharm Biomed Anal       Date:  2001-06       Impact factor: 3.935

2.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.

Authors:  S C Harris; J E Wallace; G Foulds; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

4.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Chiral high-performance liquid chromatographic analysis of antifungal SCH 56592 and evaluation of its chiral inversion in animals and humans.

Authors:  H Kim; C C Lin; M Laughlin; R Lovey; A Saksena; L Heimark; A A Nomeir
Journal:  Chirality       Date:  2000-07       Impact factor: 2.437

6.  Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma.

Authors:  Hong Kim; Pramila Kumari; Mark Laughlin; Mary Jane Hilbert; Stephen R Indelicato; Josephine Lim; Chin-Chung Lin; Amin A Nomeir
Journal:  J Chromatogr A       Date:  2003-02-14       Impact factor: 4.759

Review 7.  Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections.

Authors:  William J Steinbach; Jennifer L Reedy; Robert A Cramer; John R Perfect; Joseph Heitman
Journal:  Nat Rev Microbiol       Date:  2007-06       Impact factor: 60.633
  7 in total
  2 in total

1.  Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients.

Authors:  Isabel Sánchez-Ortega; Lourdes Vázquez; Carmen Montes; Beatriz Patiño; Montserrat Arnan; Arancha Bermúdez; Lucrecia Yáñez; Teresa Caballero; Rafael F Duarte
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

2.  Regulating Immunogenicity and Tolerogenicity of Bone Marrow-Derived Dendritic Cells through Modulation of Cell Surface Glycosylation by Dexamethasone Treatment.

Authors:  Kevin Lynch; Oliver Treacy; Jared Q Gerlach; Heidi Annuk; Paul Lohan; Joana Cabral; Lokesh Joshi; Aideen E Ryan; Thomas Ritter
Journal:  Front Immunol       Date:  2017-10-30       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.